Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes

By Wysham Carol   Lush Cameron   Zhang Bei   Maier Holly   Wilhelm Ken  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 79-85

Informa Healthcare

Access to resources Recommend Favorite

Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes

By Gæde Peter   Pedersen Oluf  

Annals of Medicine, Vol. 36, Iss. 5, 2004-09 ,pp. : 355-366

Informa Healthcare

Access to resources Recommend Favorite

New cardiovascular risk markers: The race is on, but are there any winners?

By Røsjø Helge   Omland Torbjørn  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 68, Iss. 8, 2008-01 ,pp. : 673-677

Informa Healthcare

Access to resources Recommend Favorite

Type 2 diabetes, thiazolidinediones, and cardiovascular risk

By Taylor Clare   Hobbs FD Richard  

British Journal of General Practice, Vol. 59, Iss. 564, 2009-07 ,pp. : 520-524

Royal College of General Practitioners

Access to resources Recommend Favorite

Diabetes and cardiovascular disease: time for individualized risk reduction

By McFarlane Samy I   Sowers James R  

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 451-453

Future Medicine

Access to resources Recommend Favorite